Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -5.68
- Piotroski Score 2.00
- Grade Buy
- Symbol (ADCT)
- Company ADC Therapeutics SA
- Price $1.99
- Changes Percentage (2.32%)
- Change $0.05
- Day Low $1.86
- Day High $2.00
- Year High $6.04
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/12/2025
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $13.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.77
- Trailing P/E Ratio -1.23
- Forward P/E Ratio -1.23
- P/E Growth -1.23
- Net Income $-240,053,000
Income Statement
Quarterly
Annual
Latest News of ADCT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
ADC Therapeutics SA (NYSE:ADCT) Shares Could Be 50% Below Their Intrinsic Value Estimate
The analyst's price target for ADC Therapeutics is 59% higher than their estimated fair value. A Discounted Cash Flow model is used to determine the intrinsic value of the stock, showing it to be unde...
By Yahoo! Finance | 4 months ago
